Home › Funds › ORBIMED ADVISORS LLC › XENE
ORBIMED ADVISORS LLC position in XENE
XENON PHARMACEUTICALS INC · Health Care
ORBIMED ADVISORS LLC reported holding 892,471 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$53.9M, representing 1.08% of its reported portfolio and ranking #27 among its reported holdings. ORBIMED ADVISORS LLC has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's XENE position evolved
ORBIMED ADVISORS LLC first disclosed a stake in XENE in Q3 2023 at 958,793 shares (US$32.8M). The position peaked in Q1 2026 at 1,059,971 shares, worth US$61.6M. Across 12 filings, ORBIMED ADVISORS LLC increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 892,471 shares valued at US$53.9M — a reduction of -167,500 shares quarter over quarter.. Notable position changes include a 57% increase in Q2 2024 (shares were roughly flat over the following quarter), a 56% trim in Q3 2025 (shares rose 12% over the following quarter), a 137% increase in Q1 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 958.79K | $32.75M | New |
| Q4 2023 | 550.00K | $25.33M | Reduce |
| Q1 2024 | 550.00K | $23.68M | Hold |
| Q2 2024 | 862.36K | $33.62M | Add |
| Q3 2024 | 911.42K | $35.88M | Add |
| Q4 2024 | 947.88K | $37.16M | Add |
| Q1 2025 | 947.88K | $31.80M | Hold |
| Q2 2025 | 947.88K | $29.67M | Hold |
| Q3 2025 | 419.60K | $16.85M | Reduce |
| Q4 2025 | 447.20K | $20.04M | Add |
| Q1 2026 | 1.06M | $61.64M | Add |
| Q2 2026 | 892.47K | $53.87M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XENE and 13F data
XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XENE
- Avoro Capital Advisors LLC 5.78M sh · $348.75M · Q2 2026
- Polar Capital Holdings Plc 4.57M sh · $275.88M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.42M sh · $266.70M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M sh · $97.52M · Q2 2026
- Affinity Asset Advisors, LLC 1.59M sh · $96.27M · Q2 2026
- Siren, L.L.C. 1.32M sh · $79.59M · Q2 2026
- BRAIDWELL LP 1.13M sh · $68.29M · Q2 2026
- Caligan Partners LP 889.94K sh · $53.72M · Q2 2026
- Caption Management, LLC 728.00K sh · $43.94M · Q2 2026
- Vestal Point Capital, LP 700.00K sh · $42.25M · Q2 2026
- Rock Springs Capital Management LP 683.91K sh · $41.28M · Q2 2026
- First Turn Management, LLC 600.20K sh · $36.23M · Q2 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held XENE?
ORBIMED ADVISORS LLC has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is ORBIMED ADVISORS LLC's current position in XENE?
As of Q2 2026, ORBIMED ADVISORS LLC holds 892.47K shares of XENE (XENON PHARMACEUTICALS INC), valued at $53.87M, representing 1.08% of its reported portfolio and ranking #27.
Has ORBIMED ADVISORS LLC been buying or selling XENE?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC reduced its position in XENE. The position peaked in Q1 2026 at 1.06M shares.
Which other funds hold XENE?
Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.